STAT-Dx (@statdx) 's Twitter Profile
STAT-Dx

@statdx

Our Mission is to Support Timely, Efficient Patient Care, while Optimizing Laboratory and Hospital Processes & Operations. Visit us at stat-dx.com

ID: 841608869952552960

linkhttp://www.stat-dx.com calendar_today14-03-2017 11:16:05

5 Tweet

84 Followers

1 Following

Gate.io (@gate_io) 's Twitter Profile Photo
Gate.io
@gate_io

5 hours ago

šŸ”„The 9th Round of Easy Loan, Earn $40 Reward is in progressā—ļø ā° Promotion Period: January 15th - Feburary 15th, 2025 šŸ‘‰ Register now and check more details at gate.io/campaigns/358

šŸ”„The 9th Round of Easy Loan, Earn $40 Reward is in progressā—ļø ā° Promotion Period: January 15th - Feburary 15th, 2025 šŸ‘‰ Register now and check more details at gate.io/campaigns/358
STAT-Dx (@statdx) 's Twitter Profile Photo
STAT-Dx
@statdx

8 years ago

Hello, world!! Today we are proud to unveil #DiagCORE. There is more than one way to move diagnostics #CloserToCare stat-dx.com

Business Wire-Health (@bw_health) 's Twitter Profile Photo
Business Wire-Health
@bw_health

8 years ago

Global In-Vitro Diagnostics (IVD) Market Analysis and Forecast 2017-2023: Focus on Product Type, Test Type,ā€¦ dlvr.it/PDpywg

Global In-Vitro Diagnostics (IVD) Market Analysis and Forecast 2017-2023: Focus on Product Type, Test Type,ā€¦ dlvr.it/PDpywg
STAT-Dx (@statdx) 's Twitter Profile Photo
STAT-Dx
@statdx

8 years ago

The European Investment Bank is providing STAT-Dx with a EUR 20 million loan facility. goo.gl/K4Fc3Z

STAT-Dx (@statdx) 's Twitter Profile Photo
STAT-Dx
@statdx

8 years ago

STAT-Dx announces CE-IVD mark completion for DiagCOREĀ® System and Respiratory Panel 1

STAT-Dx announces CE-IVD mark completion for DiagCOREĀ® System and Respiratory Panel 1
STAT-Dx (@statdx) 's Twitter Profile Photo
STAT-Dx
@statdx

7 years ago

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing in second half 2018 in Europe and later in the U.S.

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing in second half 2018 in Europe and later in the U.S.